AL002 misses Phase 2 goal in early Alzheimer's. Key Phase 3 data for latozinemab in 2025. Click here to read why ALEC is a ...

Noon, is tackling ALS and other neurological disorders with a bold, multi-targeted approach. Fueled by a personal encounter with an ALS advocate, Ben-Noon assembled a team of top scientists to develop ...

Obesity is a major global health issue, increasing the risk of heart disease, diabetes, and high blood pressure. Despite many ...

A person’s “bioenergetic age”—or how youthfully their cells generate energy—might be a key indicator of whether they’re at risk of developing Alzheimer’s disease, new research from Weill Cornell ...

Scientists at Scripps Research developed a stable form of carnosic acid, which enhanced memory function and improved ...

Over 30 million Americans take antidepressants. Researchers found four specific types with ties to cognition loss later in life.

Treatment with donanemab (Kisunla) raised the risk of amyloid-related imaging abnormalities (ARIA) in people with early ...

There's rosemary, that's for remembrance,' says Ophelia in Shakespeare's Hamlet. So it is fitting that researchers would study a compound found in rosemary and sage -- carnosic acid -- for its impact ...

A new study has found that using electrical stimulation on specific brain areas may help some people with Alzheimer’s disease ...

The herb rosemary has long been linked with memory: "There's rosemary, that's for remembrance," says Ophelia in Shakespeare's ...

Research suggests potential health benefits beyond what popular diabetes and weight-loss drugs were first approved to treat.

Alector said it has decided to cut about 25 employees, or 13% of its headcount, to reduce costs. The biotech company, which had been developing an Alzheimer drug candidate that missed trial endpoints ...